Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Exploring Being a parent: A Survey of \Bits of knowledge and Guidance for Guardians\ Nurturing Book - 2Excursion to Different Universes: the Top Sci-fi Motion pictures Ever
- 3Sally Rooney books may be withdrawn from UK sale over Palestine Action ban, court told
- 4How to avoid or deal with an outrageous medical bill
- 5Bad flu season getting worse; skyrocketing cases set state record
- A photographer's journey to capture a blood moon rising over the South China Sea. 'It was an incredible moment'
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- An eye for an eye: People agree about the values of body parts across cultures and eras
- Shipping: The Corridors of Trade and the Coming of Another Period
- My Excursion to Monetary Autonomy: Awesome ways to save cash
- Tech Patterns: Contraptions That Will Shape What's in store
- 25 Most Beautiful Villages in France You Can Actually Visit
- Instructions to Figure out the Various Phases of Cellular breakdown in the lungs
- Figure out How to Upgrade Your Gold Speculation Portfolio: Vital Bits of knowledge and Strategies
